Verrica Pharmaceuticals Inc., A Medical Dermatology Company, Today Announced That Its New Drug Application (Nda) For Vp-102 (Cantharidin 0.7% Topical Solution), A Proprietary Topical Therapy For The Treatment Of Molluscum Contagiosum (Molluscum), Has Been Accepted For Filing By The U.S. Food And Drug Administration (Fda). The Prescription Drug User Fee Act (Pdufa) Goal Date Assigned By The Fda For This Nda Is July 13, 2020.â
